본문 바로가기

A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1
저널
JOURNAL OF CONTROLLED RELEASE133(3) · pp.172 · 2009
피인용
Web of Science 60
JCR IF
JCR 2008 5.69
ISSN
0168-3659

저자

  1. Jin, Cheng-Hao제1저자성균관대학교, Drug Targeting Lab, Coll Pharm, KO
  2. Chae, Su Young성균관대학교, Drug Targeting Lab, Coll Pharm, KO
  3. Son, Sohee성균관대학교, Drug Targeting Lab, Coll Pharm, KO
  4. Kim, Tae Hyung성균관대학교, Drug Targeting Lab, Coll Pharm, KO
  5. Um, Key An성균관대학교, Drug Targeting Lab, Coll Pharm, KO
  6. 윤유석부산대학교, 약학대학, 약학부, 제약학전공, KO
  7. Lee, Seulki한국과학기술연구원, Biomed Res Ctr, KO
  8. Lee, Kang Choon성균관대학교, Drug Targeting Lab, Coll Pharm, KO

초록

An orally active glucagon-like peptide-1 (GLP-1) formulation would have great advantages over conventional injectable therapies for the treatment of diabetic patients. Because GLP-1 absorption in the intestine is restricted by its natural physiological characteristics, biotinylated exendin-4 analogues might useful as orally active GLP-1 receptor agonists. Three different biotinylated exendin-4 analogues, Lys(27)-Biotin-Exendin-4 (MB1-Ex-4), Lys(12)-Biotin-Exendin-4 (MB2-Ex-4), and Lys(12,) (27)-Biotin-Exendin-4 (DB-Ex-4) were prepared, and their biological activities and enzymatic stabilities were studied in vitro. The hypoglycemic effects and pharmacokinetics of these analogues after oral administration were evaluated in db/db mice and Sprague-Dawley rats, respectively. These biotinylated exendin-4 analogues preserved GLP-1 receptor binding affinity and stimulated insulin secretion in RIN-m5F murine insulinoma cells and in isolated rat islets, respectively, and were as potent as exendin-4. In particular, DB-Ex-4 showed 9.0-fold better stability against rat intestinal fluid than exendin-4. When 0.1, 1, and 10 mu g/mouse of DB-Ex-4 were orally administered, mean total hypoglycemic degrees (HGD) were increased by 36.8 +/- 1.2, 46.9 +/- 1.8, and 54.3 +/- 4.5%, respectively, whereas 1 mu g/mouse of native exendin-4 showed an increase of 8.8 +/- 7.3%. This study demonstrates that biotinylated exendin-4 analogues are absorbed in the intestine and that they have biological efficacies of exendin-4. Furthermore, it indicates that biotinylated exendin-4 analogues could be used as potential oral antidiabetic agent for the treatment of type 2 diabetes. (C) 2008 Elsevier B.V. All rights reserved.

식별자

WoS UID
000263700000002